For example, pharmacological agents able to interact with GlyR isoforms, including GlyRα1 and GlyRα3 receptors, are potentially interesting for the treatment of pain (see, for instance [2,95,96]); important GlyR-related dysfunctions are involved in neurological disorders like startle disease [125,126]; GlyRs also represent possible targets for the treatment of alcohol-use disorders [127,128]. This evidence concerns the gene GARS1 and nervous system disorder.